KRYS 188.33 ▼ -2.41% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Krystal Biotech Inc.

    NASDAQ: KRYS · Real-Time Price · USD
    188.33
    -4.66 (-2.41%)
    At close: Oct 16, 2025, 3:59 PM
    188.33
    0.00%
    After-hours: Oct 16, 2025, 05:20 PM EDT
    -2.41%
    Bid 186.8
    Market Cap 5.45B
    Revenue (ttm) 359.2M
    Net Income (ttm) 146.72M
    EPS (ttm) 4.92
    PE Ratio (ttm) 38.28
    Forward PE 23.83
    Analyst Buy
    Dividends n/a
    Ask 198.5
    Volume 207,131
    Avg. Volume (20D) 351,907
    Open 193.41
    Previous Close 192.99
    Day's Range 187.53 - 195.91
    52-Week Range 122.80 - 207.84
    Beta 0.64
    Ex-Dividend Date n/a

    About KRYS

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol KRYS
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for KRYS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Krystal Biotech Inc. is scheduled to release its earnings on Nov 3, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    2 months ago
    -14.04%
    Krystal Biotech shares are trading lower following... Unlock content with Pro Subscription
    5 months ago
    -14.06%
    Krystal Biotech shares are trading lower after the company reported worse-than-expected Q1 financial results.
    news image

    2 weeks ago · zacks.com

    Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?

    KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.

    news image

    1 month ago · zacks.com

    Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update

    KRYS shares jump after the FDA expands Vyjuvek's label to include DEB patients from birth, with added at-home use flexibility.

    news image

    1 month ago · zacks.com

    Krystal Biotech (KRYS) Up 8.5% Since Last Earnings Report: Can It Continue?

    Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?

    news image

    1 month ago · seekingalpha.com

    Krystal Biotech: A "Strong Buy" Despite KB707 Melanoma Tumor Targeting Update

    I maintain a Strong Buy on Krystal Biotech, as the pause in melanoma trial enrollment is offset by promising progress in inhaled KB707 for NSCLC. Inhaled KB707 achieved a 36% ORR in heavily pretreated...

    news image

    2 months ago · zacks.com

    KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook

    Krystal Biotech tops Q2 estimates with strong Vyjuvek sales, but shares fall 14% on weak Q3 revenue guidance.

    news image

    2 months ago · seekingalpha.com

    Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript

    Krystal Biotech, Inc. (NASDAQ:KRYS ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Kathryn A. Romano - Executive VP & Chief Accounting Officer Krish S.

    news image

    2 months ago · zacks.com

    Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates

    Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $0.86 per share a year ago.

    news image

    2 months ago · zacks.com

    Krystal Biotech, Inc. (KRYS) to Report Q2 Results: Wall Street Expects Earnings Growth

    Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Add to Watchlist